Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Should You Buy?
by Tristan Rich · The Markets DailyAstellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report)’s share price gapped up before the market opened on Monday. The stock had previously closed at $16.51, but opened at $17.10. Astellas Pharma shares last traded at $16.96, with a volume of 51,594 shares.
Wall Street Analysts Forecast Growth
Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy”.
Get Our Latest Analysis on Astellas Pharma
Astellas Pharma Stock Performance
The stock has a market capitalization of $30.93 billion, a P/E ratio of 12.53 and a beta of 0.05. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20. The company’s fifty day simple moving average is $15.25 and its two-hundred day simple moving average is $14.82.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06). Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. The firm had revenue of $3.98 billion for the quarter, compared to the consensus estimate of $3.79 billion. As a group, equities analysts forecast that Astellas Pharma Inc. will post 1.40 EPS for the current year.
About Astellas Pharma
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
Featured Articles
- Five stocks we like better than Astellas Pharma
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?